Economic impact of omitting sentinel lymph node biopsy in early breast cancer: a secondary analysis of the randomized venus trial
Introduction: The omission of sentinel lymph node biopsy (SLNB) in early breast cancer patients who are clinically node-negative has been explored. However, data regarding the economic implications of this strategy remain limited. The VENUS trial is designed to evaluate SLNB omission. Objective: This report presents a...